Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zivin, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zivin, J. A.
Neurology 1999;53:14
© 1999 American Academy of Neurology


Views & Reviews

Thrombolytic stroke therapy

Past, present, and future*

Justin A. Zivin, MD, PhD

From the University of California, San Diego.

Address correspondence and reprint requests to Dr. Zivin, University of California, San Diego, Department of Neurosciences, 9500 Gilman Drive, La Jolla, CA 92093-0624; e-mail: jzivin{at}ucsd.edu

Article Abstract

Until 1995, treatment of strokes consisted exclusively of efforts to prevent recurrence. Proof that tissue plasminogen activator is useful for acute management is changing the approach to stroke patients. The development process has been difficult and the current treatment recommendations have been controversial. Recent successful clinical trials lend additional credence to these concepts. Future treatment strategies will probably include combinations of thrombolytics and neuroprotectants of various types. However, the need to initiate treatment rapidly after stroke onset is likely to continue.




This article has been cited by other articles:


Home page
StrokeHome page
P. A. Lapchak, M.-K. Han, K. F. Salgado, J. Streeter, and J. A. Zivin
Safety Profile of Transcranial Near-Infrared Laser Therapy Administered in Combination With Thrombolytic Therapy to Embolized Rabbits
Stroke, November 1, 2008; 39(11): 3073 - 3078.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
L. Zhang, Z. G. Zhang, G. L. Ding, Q. Jiang, X. Liu, H. Meng, A. Hozeska, C. Zhang, L. Li, D. Morris, et al.
Multitargeted Effects of Statin-Enhanced Thrombolytic Therapy for Stroke With Recombinant Human Tissue-Type Plasminogen Activator in the Rat
Circulation, November 29, 2005; 112(22): 3486 - 3494.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
A. V. Alexandrov, C. E. Hall, L. A. Labiche, A. W. Wojner, and J. C. Grotta
Ischemic Stunning of the Brain: Early Recanalization Without Immediate Clinical Improvement in Acute Ischemic Stroke
Stroke, February 1, 2004; 35(2): 449 - 452.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
P. A. Lapchak and J. A. Zivin
Ebselen, a Seleno-Organic Antioxidant, Is Neuroprotective After Embolic Strokes in Rabbits: Synergism With Low-Dose Tissue Plasminogen Activator
Stroke, August 1, 2003; 34(8): 2013 - 2018.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
L. Zhang, Z. G. Zhang, R. L. Zhang, M. Lu, M. Krams, and M. Chopp
Effects of a Selective CD11b/CD18 Antagonist and Recombinant Human Tissue Plasminogen Activator Treatment Alone and in Combination in a Rat Embolic Model of Stroke
Stroke, July 1, 2003; 34(7): 1790 - 1795.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
M. Fisher
Recommendations for Advancing Development of Acute Stroke Therapies: Stroke Therapy Academic Industry Roundtable 3
Stroke, June 1, 2003; 34(6): 1539 - 1546.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
P. A. Lapchak, D. M. Araujo, S. Pakola, D. Song, J. Wei, and J. A. Zivin
Microplasmin: A Novel Thrombolytic That Improves Behavioral Outcome After Embolic Strokes in Rabbits
Stroke, September 1, 2002; 33(9): 2279 - 2284.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
C.J.M. Frijns and L.J. Kappelle
Inflammatory Cell Adhesion Molecules in Ischemic Cerebrovascular Disease
Stroke, August 1, 2002; 33(8): 2115 - 2122.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
H. C. Diener, E. B. Ringelstein, R. von Kummer, H. D. Langohr, H. Bewermeyer, H. Landgraf, M. Hennerici, D. Welzel, M. Grave, J. Brom, et al.
Treatment of Acute Ischemic Stroke With the Low-Molecular-Weight Heparin Certoparin : Results of the TOPAS Trial
Stroke, January 1, 2001; 32(1): 22 - 29.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
P. A. Lapchak, D. F. Chapman, J. A. Zivin, and C. Y. Hsu
Metalloproteinase Inhibition Reduces Thrombolytic (Tissue Plasminogen Activator)-Induced Hemorrhage After Thromboembolic Stroke Editorial Comment
Stroke, December 1, 2000; 31(12): 3034 - 3040.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
G. DEVUYST and N. AFSAR
Is transcranial colour Duplex flow imaging of use in selection of patients with acute stroke for thrombolysis?
J. Neurol. Neurosurg. Psychiatry, June 1, 2000; 68(6): 794 - 794.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by AAN Enterprises, Inc.